Sandlie group

Inger Sandlie heads a group that studies the structure and function of antibodies and T-cell receptors and engineer these spesific immune system detectors for use in therapy and as research tools.

Inger Sandlie

About the group

The purpose of our work is to engineer soluble T cell receptors, antibodies and antibody derived molecules to be used in therapy and as research reagents.


Our main areas of interest are stability and affinity engineering of binding molecules. Most projects involve close collaboration with other research groups within the Centre for Immune Regulation. Some projects also bridge protein engineering with applications, such as the development of subunit vaccine reagents.

We focus on two projects:

  1. Studies of the interaction between Fc receptors, and in particular the neonatal Fc receptor, with IgG subclasses and albumin. Key questions are how ligand binding elicits antibody effector functions of IgG subclasses and regulate serum half life.
  2. Expression of soluble T cell receptors for the detection of complexes between antigenic peptides and HLA molecules, as well as peptide – HLA complexes for detection of T cell receptors. The focus is on engineering to increase stability and affinity for molecules that are characteristic of disease models in groups at CIR.

Read more about the Sandlie group at the Department of Molecular Biosciences.

Read more about molecular biology and protein engineering.

Selected publications

  • J.T. Andersen, B. Dalhus, J. Cameron, M.B. Daba, A. Plumridge, L. Evans, S.O. Brennan, K.S. Gunnarsen, M. Bjørås, D. Sleep and I. Sandlie, I. (2012). Structure-Based Mutagenesis Reveals the Albumin Binding Site for the Neonatal Fc Receptor. Nature Commun. Jan 3;3:610
  • Brekke, O.H. and Sandlie, I. (2003). Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nature Reviews, Drug Discovery, 2:52-62.
  • Rasmussen, I.B., Lunde, E., Michaelsen, T.E., Bogen, B. and Sandlie, I. (2001). The principle of delivery of T cell epitopes to antigen presenting cells applied to peptides from influenza virus, ovalbumin and hen egg lysozyme: Implications for peptide vaccination. Proc. Natl. Acad. Sci. USA, 98:10296.
  • Lunde, E., Munthe, L.A., Vabø, A., Sandlie, I. and Bogen, B. (1999). Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antigen presentation by B cells. Nature Biotechnology, 17:670-675.
  • Brekke, O.H., Michaelsen, T.E., Sandin, R. and Sandlie, I. (1993). Activation of complement by an IgG3 molecule without genetic hinge. Nature 363:628-630.
Published Jan. 26, 2012 4:47 PM - Last modified Sep. 11, 2017 8:33 PM


  • Department of Immunology, Oslo University Hospital Rikshospitalet and University of Oslo, PO Box 4950 Nydalen, Oslo 0424, Norway.
  • Department of Molecular Biosciences, University of Oslo, PO box 1041, Blindern, Oslo 0316, Norway.


Group leader